The short version of PPARδ agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-03 and is reviewed periodically as new material appears.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
== Biosynthesis == The apelin gene encodes a pre-proprotein of 77 amino acids, with a signal peptide in the N-terminal region. After translocation into the endoplasmic reticulum and cleavage of the signal peptide, the proprotein of 55 amino acids may generate several active fragments: a 36 amino acid peptide corresponding to the sequence 42-77 (apelin 36), a 17 amino acid peptide corresponding to the sequence 61-77 (apelin 17) and a 13 amino acid peptide corresponding to the sequence 65-77 (apelin 13). This latter fragment may also undergo a pyroglutamylation at the level of its N-terminal glutamine residue. However the presence and/or the concentrations of those peptides in human plasma has been questioned. Recently, 46 different apelin peptides ranging from apelin 55 (proapelin) to apelin 12 have been identified in bovine colostrum, including C-ter truncated isoforms.
In the early nineteenth century, it was still undecided which port would be chosen as the primary sea link along the route from London to Dublin: Porthdinllaen, on the Llŷn Peninsula, or Holyhead in Anglesey. In May 1806, the Porthdinlleyn Harbour Act 1806 (46 Geo. 3. c. xxxiv) approved new buildings in Porthdinllaen when it seemed that the town would be chosen. Porthdinllaen was almost as far west as Holyhead, but Holyhead was more accessible because of Thomas Telford's road developments. Porthdinllaen Harbour Company was formed in 1808 in preparation, but the bill before Parliament to constitute Porthdinllaen as a harbour for Irish trade was rejected in 1810. Holyhead's maritime importance was at its height in the 19th century with a 1+3⁄4-mile-long (2.8-kilometre) sea breakwater. Holyhead Breakwater, built to create a safe harbour for vessels caught in stormy waters on their way to Liverpool and the industrial ports of Lancashire; it is the longest breakwater in the UK. Throughout the later 18th century and the entire 19th century, Holyhead was a crucial transit point for landed gentry and British parliamentarians and military officials who were travelling from Ireland to London. It was also a transit point for British owners of multinational estates visiting their 'other lands' or London houses. The port of Holyhead saw significant development throughout the 19th century to accommodate the growing passenger traffic between Holyhead and Dublin, which reached approximately 14,000 passengers annually by 1814.
== Adverse effects == Besides being a hepatocarcinogen, safrole exhibits further adverse effects in that it will induce the formation of hepatic lipid hydroperoxides. Safrole also inhibits the defensive function of neutrophils against bacteria. In addition to the inhibition of the defensive function of neutrophils, it has also been discovered that safrole interferes with the formation of superoxides by neutrophils. Furthermore, safrole oxide, a metabolite of safrole, has a negative effect on the central nervous system. Safrole oxide inhibits the expression of integrin β4/SOD, leading to apoptosis of the nerve cells.
Sources: en.wikipedia.org
Regulation of transcription can be broken down into three main routes of influence; genetic (direct interaction of a control factor with the gene), modulation interaction of a control factor with the transcription machinery and epigenetic (non-sequence changes in DNA structure that influence transcription).
Zverev's first ATP event of the year was the 2016 Australian Open, where he had a difficult draw against world No. 2 Andy Murray and was only able to win six games in his opening match. He bounced back at the Open Sud de France, reaching the semifinals in the singles event and his second career final with his brother in the doubles event. During the singles event, he upset No. 13 Marin Čilić, the highest-ranked player he had defeated in an official match at the time. Zverev then produced a strong result at the Indian Wells Masters, where he defeated two top 30 players. In the fourth round, he nearly upset No. 5 Rafael Nadal. Zverev had a match point while he was serving for the final set, but missed a routine forehand volley and then proceeded to lose 14 of the remaining 15 points in the match. He commented on the match point that, "I missed probably the easiest shot I had the whole match." Back in Europe, Zverev was able to recover as he reached his first ATP singles final at the Open de Nice Côte d'Azur, finishing runner-up to No. 15 Dominic Thiem, the top seed and defending champion. Thiem also defeated him in the third round of the French Open.
Cossack relations with the Tsardom of Russia were varied from the outset. At times they supported Russian military operations, at other times they rebelled against the central power. After one such uprising at the end of the 18th century, Russian forces destroyed the Zaporozhian Host. Many of the Cossacks who had remained loyal to the Russian Monarch and continued their service later moved to the Kuban. Others, choosing to continue a mercenary role, escaped control in the large Danube Delta. The service of the Cossacks in the Napoleonic wars led them to be celebrated as Russian folk heroes, and throughout the 19th century a "powerful myth" was promoted by the government that portrayed the Cossacks as having a special and unique bond to the Emperor. This image of the Cossacks as ultra-patriotic defenders of not only Russia, but also of the House of Romanov was embraced by many ordinary Cossacks, making them into a force for conservatism. By the 19th century, the Russian Empire had annexed the territory of the Cossack Hosts, and controlled them by providing privileges for their service such as exemption from taxation and allowing them to own the land they farmed. At this time, the Cossacks served as military forces in many wars conducted by the Russian Empire. Cossacks were considered excellent for scouting and reconnaissance duties, and for ambushes. Their tactics in open battle were generally inferior to those of regular soldiers, such as the Dragoons.
=== Repair of Oxidative damage === Secondary defenses include DNA-repair systems, proteolytic and lipolytic enzymes. DNA repair enzymes include endonuclease IV, induced by oxidative stress, and exonuclease III, induced in the stationary phase and in starving cells. These enzymes act on duplex DNA and clean up DNA 3' terminal ends. Prokaryotic cells contain catalysts that modify the primary structure of proteins frequently by reducing disulfide bonds. This occurs in the following steps: (i) thioredoxin reductase transfers electrons from NADPH to thioredoxin via a flavin carrier (ii) glutaredoxin is also able to reduce disulfide bonds, but using GSH as an electron donor (iii) protein disulfide isomerase facilitates disulfide exchange reactions with large inactive protein substrates, besides having chaperone activity Oxidation of surface exposed methionine residues surrounding the entrance to the active site could function as a “last-chance” antioxidant defense system for proteins.
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.